Aptorum Group Limited (NASDAQ:APM – Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 4,200 shares, a decline of 30.0% from the August 31st total of 6,000 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 13,700 shares, the short-interest ratio is presently 0.3 days.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Aptorum Group stock. Murchinson Ltd. acquired a new position in shares of Aptorum Group Limited (NASDAQ:APM – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned about 0.27% of Aptorum Group at the end of the most recent reporting period. Institutional investors own 3.80% of the company’s stock.
Aptorum Group Trading Down 1.3 %
APM stock traded down $0.02 during midday trading on Friday, hitting $1.85. The company’s stock had a trading volume of 15,262 shares, compared to its average volume of 830,728. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.20. Aptorum Group has a twelve month low of $1.35 and a twelve month high of $17.49. The company’s fifty day moving average price is $2.92 and its 200 day moving average price is $4.73.
About Aptorum Group
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.
Featured Stories
- Five stocks we like better than Aptorum Group
- How to invest in marijuana stocks in 7 steps
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- What does consumer price index measure?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Consumer Staples Stocks, Explained
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Aptorum Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptorum Group and related companies with MarketBeat.com's FREE daily email newsletter.
